ASX Share rice
Mon 17 May 2021 - 05:22:am (Sydney)

IMU Share Price

IMUGENE LIMITEDIMUPharmaceuticals, Biotechnology & Life Sciences

IMU Company Information

Name:

Imugene Limited

Sector:

Healthcare

Industry:

Biotechnology

GIC Industry:

Biotechnology

GIC Sub Industry:

Biotechnology

Address:

37 Bligh Street Sydney NSW Australia 2000

Phone:

61 3 9824 5254

Exec. Chairman:

Mr. Paul Edward-Alexander Hopper

CEO, MD & Exec. Director:

Ms. Leslie Chong

CTO & COO:

Dr. Nicholas J. Ede

CFO & Joint Company Sec.:

Mr. Phillip Allen Hains

Chief Medical Officer:

Dr. Rita Laeufle M.D., Ph.D.

Joint Company Sec.:

Mr. Justyn Peter Stedwell B.Com., B.Com

Company Overview:

Imugene Limited, a clinical stage immuno-oncology company, develops a range of immunotherapies to activate the immune system of cancer patients to treat and eradicate tumors in Australia. Its lead product is HER-Vaxx, a HER2-positive cancer vaccine that stimulates a polyclonal antibody response against HER2/neu receptors in gastric and breast cancer. The company's HER-Vaxx is in Phase 1b/2 study for gastric cancer. It also engages in developing PD1-Vaxx, a cancer vaccine that aims to induce the body to produce polyclonal antibodies that block PD-1 signalling; B-Vaxx, a cancer vaccine to treat tumors that over-express the HER2/neu receptor; and CF-33, a combination of genomic sequences from various vaccinia virus strains to generate potent virus. Imugene Limited was incorporated in 1986 and is headquartered in Sydney, Australia.

IMU Share Price Information

Shares Issued:

4.79B

Market Capitalisation:

$1.39B

Revenue (TTM):

$5.87M

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.002

Profit Margin:

-2.007

Operating Margin (TTM):

$-2.03

Return On Assets (TTM):

$-0.11

Return On Equity (TTM):

$-0.18

Quarterly Revenue Growth (YOY):

0.731

Gross Profit(TTM):

$4.13M

Diluted Earnings Per Share (TTM):

$-0.003

IMU CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-30,638

Change To Liabilities:

$-999,940

Total Cashflow From Investing Activities:

$-1,206,652

Net Borrowings:

$-53,560

Net Income:

$-10,507,999

Total Cash From Operating Activities:

$-10,437,765

Depreciation:

$82.50K

Other Cashflow From Investing Activities:

$310.68K

Change To Account Receivables:

$-33,574

Sale Purchase Of Stock:

$24.57M

Capital Expenditures:

$5.03K

IMU Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-10,508,000

Net Income:

$-10,508,000

Operating Income:

$-10,805,160

Interest Expense:

$136.80K

Total Revenue:

$4.21M

IMU Balance Sheet

Balance Sheet Date:

2020-06-30

Intangible Assets:

$30.46M

Total Liabilities:

$5.40M

Total Stockholder Equity:

$59.81M

Other Current Liabilities:

$1.44M

Total Assets:

$65.20M

Common Stock:

$92.80M

Other Current Assets:

$194.06K

Retained Earnings:

$-47,310,259

Other Liabilities:

$2.49M

Other Assets:

$15.59K

Cash:

$30.11M

Total Current Liabilities:

$2.90M

Property - Plant & Equipment:

$155.62K

Net Tangible Assets:

$29.35M

Long-Term Investments:

$80.64K

Total Current Assets:

$34.49M

Net Receivables:

$4.19M

Short-Term Investments:

$30.71M

Accounts Payable:

$1.01M

Non Currrent Assets (Other):

$15.59K

Short-Term Investments:

$30.71

Non Current Liabilities (Other):

$2.49M

Non Current Liabilities Total:

$2.50M

IMU Share Price History

IMU News

11 Dec, 2020
Long term investing can be life changing when you buy and hold the truly great businesses. And highest quality...
10 Sep, 2020
Leslie Chong became the CEO of Imugene Limited (ASX:IMU) in 2016, and we think it's a good time to look at the...
23 May, 2020
The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on a lighter note, a...